vascuCAP vs VX1
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
These two tools are adjacent rather than direct competitors, as they address distinct clinical needs within cardiology. vascuCAP focuses on non-invasive CT angiography analysis for cardiovascular risk assessment and plaque characterization. In contrast, VX1 provides real-time AI guidance to cardiac electrophysiologists during atrial fibrillation and atrial tachycardia ablation procedures.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
vascuCAP (now ElucidVivo/PlaqueIQ) is an AI software for non-invasive CT angiography analysis, quantifying plaque composition and assessing cardiovascular risk to optimize treatment decisions. VX1 is an FDA-cleared AI software that assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures.
vascuCAP is designed for Cardiology, Radiology, and Vascular Surgery specialties. VX1 is specifically tailored to assist cardiologists, particularly cardiac electrophysiologists, during AFib and atrial tachycardia ablation procedures.
vascuCAP analyzes non-invasive CT angiogram data to quantify plaque composition and characterize features like lipid-rich necrotic core, calcification, non-calcified matrix, and intraplaque hemorrhage. VX1 analyzes 3D anatomical and electrical maps of human atria and electrograms in real-time to identify dispersed electrograms.
vascuCAP provides histologically-validated plaque quantification and characterization, 3D visualization of arterial vessels and plaque, and risk stratification for stroke and heart attack, supporting personalized treatment decisions. VX1 offers AI-guided real-time identification of dispersed electrograms, aims to reduce inter-operator variability, and standardizes outcomes during AFib and atrial tachycardia ablation procedures.
vascuCAP is explicitly stated as HIPAA compliant and offers a Business Associate Agreement (BAA). For VX1, FDA clearance is stated, but HIPAA compliance and the availability of a BAA are not explicitly mentioned in the provided information.